Blood coagulation: a powerful bactericidal mechanism of human innate immunity

International Reviews of Immunology

Volumn 38, Issue 1, 2019, Pages 3-17

  Minasyan, Hayk ^a   Flachsbart, Friedrich ^b  

^a Private Laboratory Immunology Microbiology   (Armenia)

^b Hospital Longlern   (Germany)

Author keywords

Coagulation; erythrocytes; innate immunity; leukocytes; platelets

Indexed keywords

ANTIBIOTIC AGENT; ANTICOAGULANT AGENT; BLOOD CLOTTING FACTOR; HEMOGLOBIN; OXYGEN; OXYHEMOGLOBIN; THROMBOCYTE FACTOR; ANTIINFECTIVE AGENT;

ANTICOAGULATION; BACTERICIDAL ACTIVITY; BLOOD CLOTTING; DEHYDRATION; DISSEMINATED INTRAVASCULAR CLOTTING; ERYTHROCYTE; HUMAN; INNATE IMMUNITY; MONOCYTE; NEUTROPHIL; NONHUMAN; OSMOTIC STRESS; PRIORITY JOURNAL; REVIEW; IMMUNOLOGY; MACROPHAGE; METABOLISM; PHYSIOLOGY; THROMBOCYTE;

ANTI-BACTERIAL AGENTS; BLOOD COAGULATION; BLOOD PLATELETS; ERYTHROCYTES; HUMANS; IMMUNITY, INNATE; INFECTIONS; MACROPHAGES; NEUTROPHILS; OXYHEMOGLOBINS;

EID: 85063813508     PISSN: 08830185     EISSN: 15635244     Source Type: Journal    
DOI: 10.1080/08830185.2018.1533009     Document Type: Review

References (159)

1. Delvaeye M, Conway EM. Coagulation and innate immune responses: Can we view them separately? Blood 2009;114(12):2367–2374.
2. Loof TG, Mörgelin M, Johansson L, et al. Coagulation, an ancestral serine protease cascade, exerts a novel function in early immune defense. Blood 2011;118(9):2589–2598.
3. Page MJ, Di Cera E. Serine peptidases: classification, structure and function. Cell Mol Life Sci 2008;65(7–8):1220–1226.
4. Schroeder V, Kohler HP. New developments in the area of factor XIII. J Thromb Haemost 2013; Feb; 11(2):234–244.
5. Dickneite G, Herwald H, Korte W, Allanore Y, Denton CP, Matucci Cerinic M. Coagulation factor XIII: a multifunctional transglutaminase with clinical potential in a range of conditions. Thromb Haemost 2015;113(04):686–697.
6. Wang Z, Wilhelmsson C, Hyrsl P. Pathogen entrapment by transglutaminase—a conserved early innate immune mechanism. PLoS Pathog 2010;6(2):e1000763
7. Armstrong MT, Rickles FR, Armstrong PB. Capture of lipopolysaccharide (endotoxin) by the blood clot: a comparative study. PLoS One 2013;8(11):e80192
8. Cines DB, Lebedeva T, Nagaswami C, et al. Clot contraction: compression of erythrocytes into tightly packed polyhedra and redistribution of platelets and fibrin. Blood 2014;123(10):1596–1603. doi: 10.1182/blood-2013-08-523860
9. Kasahara K, Kaneda M, Miki T, et al. Clot retraction is mediated by factor XIII-dependent fibrin-αIIbβ3-myosin axis in platelet sphingomyelin-rich membrane rafts. Blood 2013;122(19):3340–3348.
10. Jen CJ, McIntire LV. The structural properties and contractile force of a clot. Cell Motil 1982;2(5):445–455.
11. Carr ME., Jr., Development of platelet contractile force as a research and clinical measure of platelet function. Cell Biochem Biophys 2003;38(1):55–78.
12. Lee SJ, Trostel A, Le P, Harinarayanan R, Fitzgerald PC, Adhya S. Cellular stress created by intermediary metabolite imbalances. Proc Natl Acad Sci USA 2009;106(46):19515–19520.
13. Ray JCJ, Wickersheim ML, Jalihal AP, Adeshina YO, Cooper TF, Balázsi G. Cellular GrowthArrestandPersistencefromEnzyme Saturation. PLoS Comput Biol 2016;12(3):e1004825. doi: 10.1371/journal.pcbi.1004825
14. Konopka A, Furbacher P, Gedney C. Introduction to microbiology. London: Pearson Education Limited. 2003.
15. Lehman D. Introduction to Microbiology. Dubuque, Iowa: Kendall Hunt Pub Co; 2003.
16. Wilson M, Mcnab R, Henderson B. Bacterial disease mechanisms: An introduction to cellular microbiology. Cambridge: Cambridge University Press; 2002.
17. Sun H. The interaction between pathogens and the host coagulation system. Physiology (Bethesda) 2006; Aug; 21:281–288.
18. Travis J, Potempa J. Bacterial proteinases as targets for the development of second-generation antibiotics. Biochim Biophys Acta 2000;1477(1–2):35–50.
19. Oleksy A, Golonka E, Bańbuła A, et al. Growth phase-dependent production of a cell wall-associated elastinolytic cysteine proteinase by Staphylococcus epidermidis. Biol Chem 2004;385(6):525–535.
20. Harris TO, Shelver DW, Bohnsack JF, Rubens CE. A novel streptococcal surface protease promotes virulence, resistance to opsonophagocytosis, and cleavage of human fibrinogen. J Clin Invest 2003;111(1):61–70.
21. Mosesson MW. Fibrinogen and fibrin structure and functions. J Thromb Haemost 2005;3(8):1894–1904.
22. Wolberg AS. Thrombin generation and fibrin clot structure. Blood Rev 2007;21(3):131–142.
23. Collet JP, Moen JL, Veklich YI, et al. The alphaC domains of fibrinogen affect the structure of the fibrin clot, its physical properties, and its susceptibility to fibrinolysis. Blood 2005;106(12):3824–3830.
24. Weisel JW, Medved L. The structure and function of the alpha C domains of fibrinogen. Ann N Y Acad Sci 2001;936:312–327.
25. Si F, Li B, Margolin W, Sun SX. Bacterial growth and form under mechanical compression. Sci Rep 2015;5:11367art.no.
26. Jiang HY, Sun SX. Morphology, growth, and size limit of bacterial cells. Phys Rev Lett 2010;105(2):028101
27. Kumar P, Libchaber A. Pressure and temperature dependence of growth and morphology of Escherichia coli: experiments and stochastic model. Biophys J 2013;105(3):783–793.
28. Zhou X, Halladin DK, Rojas ER, et al. Bacterial division. Mechanical crack propagation drives millisecond daughter cell separation in Staphylococcus aureus. Science 2015;348(6234):574–578. ()
29. Potts M. Desiccation tolerance of prokaryotes. Microbiol Rev 1994;58(4):755–805.
30. Klinger MHF, Ulbricht T. Participation of human blood platelets in antimicrobial host defense. Transfus Med Hemother 2003;30(2):57–62.
31. Dankert J, vanDer Werff J, Zaat SAJ, Joldersma W, Klein D, Hess J. Involvement of bactericidal factors from thrombin-stimulated platelets in clearance of adherent viridans streptococci in experimental infective endocarditis. Inf Immun 1995;63(2):663–671.
32. Moojen DJ, Everts PA, Schure RM, et al. Antimicrobial activity of platelet-leukocyte gel against Staphylococcus aureus. J Orthop Res 2008;26(3):404–410.:
33. Trowbridge CC, Stammers AH, Woods E, Yen BR, Klayman M, Gilbert C. Use of platelet gel and its effects on infection in cardiac surgery. J Extra Corpor Technol 2005;37(4):381–386.
34. Ali RA, Wuescher LM, Keith R, Dona KR, Worth RG. Platelets mediate host defense against staphylococcus aureus through direct bactericidal activity and by enhancing macrophage activities. JI 2017;198(1):344–351.
35. Yeaman MR. The role of platelets in antimicrobial host defense. Clin Infect Dis 1997;25(5):951–968.
36. Klinger MH, Jelkmann W. Role of blood platelets in infection and inflammation. J Interferon Cytokine Res 2002;22(9):913–922.
37. Tang YQ, Yeaman MR, Selsted ME. Antimicrobial peptides from human platelets. Infect Immun 2002;70(12):6524–6533.
38. Semple JW, Italiano JE, Freedman J. Platelets and the immune continuum. Nat Rev Immunol 2011;11(4):264–274.
39. Clark SR, Ma AC, Tavener SA, McDonald B, Goodarzi Z, Kelly MM. Platelet TLR4 activates neutrophil extracellular traps to ensnare bacteria in septic blood. Nat Med 2007;13(4):463–469.
40. Costanzo LS. Physiology. Hagerstown, Maryland: Lippincott Williams & Wilkins. 2007.
41. Minasyan H. Erythrocyte and blood antibacterial defense. Eur J Microbiol Immunol (Bp) 2014;4(2):138–233.
42. Minasyan H. Mechanisms and pathways for the clearance of bacteria from blood circulation in health and disease. Pathophysiology 2016;23:61–66.
43. Hodson D, Hirsch JG. The antibacterial activity of hemoglobin. J Exp Med 1958;107(2):167–183.
44. Sheshadri P, Abraham J. Antimicrobial properties of hemoglobin. Immunopharmacol Immunotoxicol 2012;34(6):896–900.
45. Mak P, Wójcik K, Silberring J, Dubin A. Antimicrobial peptides derived from heme-containing proteins: Hemocidins. Antonie Van Leeuwenhoek 2000;77(3):197
46. Mak P. Hemocidins in a functional and structural context of human antimicrobial peptides. Front Biosci 2008;13:6859–6871.
47. Liepke C, Baxmann S, Heine C, Breithaupt N, Ständker L, Forssmann WG. J Human hemoglobin-derived peptides exhibit antimicrobial activity: a class of host defense peptides. Chromatogr B Analyt Technol Biomed Life Sci 2003;791(1-2):345–356.
48. Pichereau V, Hartke A, Auffray Y. Starvation and osmotic stress induced multiresistances: influence. of Extracellular Compounds. Int J Food Microbiol 2000;55(1-3):19–25.
49. Csonka LN. Physiological and genetic responses of bacteria to osmotic stress. Microbiol Rev 1989; 53(1):121–147.
50. Semeraro N, Ammollo CT, Semeraro F, Colucci M. Sepsis-associated disseminated intravascular coagulation and thromboembolic disease. Mediterr J Hematol Infect Dis 2010;132(3):e2010024
51. Wada H, Matsumoto T, Yamashita Y. Diagnosis and treatment of disseminated intravascular coagulation (DIC) according to four DIC guidelines. J Intensive Care 2014;2(1):1520
52. Kälsch T, Elmas E, Nguyen XD, et al. Endotoxin-induced effects on platelets and monocytes in an in vivo model of inflammation. Basic Res Cardiol 2007; 102(5):460–466.
53. Levi M, Schultz M, van der Poll T. Sepsis and thrombosis. Semin Thromb Hemost 2013;39(5):559–566.
54. Venugopal A. Disseminated intravascular coagulation. Indian J Anaesth 2014; Sep58(5):603–608.
55. Davis RP, Miller-Dorey S, Jenne CN. Platelets and coagulation in infection. Clin Transl Immunol 2016;85(7):e89
56. Freeman BD, Buchman TG. Coagulation inhibitors in the treatment of sepsis. Expert Opin Investig Drugs 2002;11(1):69–74.
57. Griffin JH, Fernandez JA, Gale AJ, Mosnier LO. Activated protein C. J Thromb Haemost 2007;5(1):73–80.
58. Fourrier F, Chopin C, Goudemand J, et al. Septic shock, multiple organ failure, and disseminated intravascular coagulation. Compared patterns of antithrombin III, protein C, and protein S deficiencies. Chest 1992;101(3):816–823.
59. Levi M, van der Poll T. Recombinant human activated protein C: current insights into its mechanism of action. Crit Care 2007;11(Suppl 5):S3.
60. Bernard GR, Ely EW, Wright TJ. Safety and dose relationship of recombinant human activated protein C for coagulopathy in severe sepsis. Crit Care Med 2001;29(11):2051–2059.
61. Bernard GR, Vincent JL, Laterre PF, et al. Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med 2001;344(10):699–709.
62. Fumagalli R, Mignini MA. The risk profile of drotrecogin alfa (activated). Crit Care 2007;11(Suppl 5):S6–S6.
63. Ely EW, Laterre P-F, Angus DC, et al. Drotrecogin alfa (activated) administration across clinically important subgroups of patients with severe sepsis. Crit Care Med 2003;31(1):12–19.
64. Abraham E, Laterre PF, Garg R, et al. Drotrecogin alfa (activated) for adults with severe sepsis and a low risk of death. N Engl J Med 2005;353(13):1332–1341.
65. Nadel S, Goldstein B, Williams MD, et al. Drotrecogin alfa (activated) in children with severe sepsis: a multicentre phase III randomised controlled trial. Lancet 2007;369(9564):836–843.
66. Carlet J. Prescribing indications based on successful clinical trials in sepsis: a difficult exercise. Crit Care Med 2006;34(2):525–529.
67. Ranieri VM, Thompson BT, Barie PS, et al. Drotrecogin alfa (activated) in adults with septic shock. N Engl J Med 2012;366(22):2055–2064.
68. Fourrier F, Jourdain M, Tournoys A. Clinical trial results with antithrombin III in sepsis. Crit Care Med 2000;28(9 Suppl):S38–S43.
69. Allingstrup M, Wetterslev J, Ravn FB, Møller AM, Afshari A. Antithrombin III for critically ill patients: a systematic review with meta-analysis and trial sequential analysis. Systematic Review. Intensive Care Med 2016;42(4):505–520.
70. Roberts HR, Hoffman M, Monroe DM. A cell-based model of thrombin generation. Semin Thromb Hemost 2006;32(1):32–38.
71. Mousa SA, Fareed J, Iqbal O, Kaiser B. Tissue factor pathway inhibitor in thrombosis and beyond. Methods Mol Med. 2004;93:133–155.
72. Broze GJ, Warren LA, Novotny WF, Higuchi DA, Girard JJ, Miletich JP. The lipoprotein-associated coagulation inhibitor that inhibits the factor VIIa-tissue factor complex, also inhibits factor Xa: insight into its possible mechanism of action. Blood 1988;71:335–343.
73. Sandset PM, Abildgaard U, Larsen ML. Heparin induces release of extrinsic coagulation pathway inhibitor (EPI). Thromb Res 1988;50(6):803–813.
74. Fareed J, Hoppensteadt D, Jeske W, Clarizio R, Walenga JM. Low molecular weight heparins. Are They Different? Can J Cardiol 1998;14:28–34.
75. Liu XIAO-LI, Wang XIAO-ZHI, Liu XIU-XIANG, et al. Low-dose heparin as treatment for early disseminated intravascular coagulation during sepsis: A prospective clinical study. Exp Therap Med 2014;7(3):604–608., ().
76. Shen JI, Winkelmayer WC. Use and safety of unfractionated heparin for anticoagulation during maintenance hemodialysis. Am J Kidney Dis 2012;60(3):473–486.
77. Zarychanski R, Abou-Setta AM, Kanji S, et al. Heparin in patients with sepsis, septic shock, and disseminated intravascular coagulation associated with infection may be associated with decreased mortality. Crit Care Med 2015;43(3):511–518.
78. Umemura Y, Yamakawa K, Ogura H, Yuhara H, Fujimi SJ. Efficacy and safety of anticoagulant therapy in three specific populations with sepsis: a meta-analysis of randomized controlled trials. J Thromb Haemost 2016;14(3):518–530.
79. Zhao C, Zhang ZD, Zhang XJ, Li X, Zhu R, Ma XC. Evaluation of clinical effects on low-dose heparin therapy for sepsis. Zhonghua Nei Ke Za Zhi 2009;48(7):566–569.
80. Wang C, Chi C, Guo L, et al. Heparin therapy reduces 28-day mortality in adult severe sepsis patients: a systematic review and meta-analysis. Crit Care 2014;18(5):563.
81. Yang CH, Guan XD, Chen J, et al. The study of the mechanism of the effect of heparin on tissue perfusion of sepsis patients. Zhongguo Wei Zhong Bing Ji Jiu Yi Xue 2008;20(9):550–552.
82. Liu Z, Zhu H, Ma X. Heparin for treatment of sepsis: a systemic review. Zhonghua Wei Zhong Bing Ji Jiu Yi Xue 2014;26(3):135–141.
83. Levi M, Toh CH, Thachil J, Watson HG. Guidelines for the diagnosis and management of disseminated intravascular coagulation. British Committee for Standards in Haematology. Br J Haematol 2009;145(1):24–33. Apr
84. Wada H, Thachil J, Di Nisio M, et al. Guidance for diagnosis and treatment of DIC from harmonization of the recommendations from three guidelines. J Thromb Haemost 2013; doi: 10.1111/jth.12155. [Epub ahead of print]
85. Norberg B, Bandmann U, Rydgren L. Amoeboid movement in human leucocytes: basic mechanisms, cytobiological and clinical significance. J Mechanochem Cell Motil 1977;4(1):37–53.
86. Jacob M, Chappell D, Rehm M. The 'third space'-fact or fiction? Best Pract Res Clin Anaesthesiol 2009;23(2):145–157.
87. Dorland N. Dorland's Illustrated Medical Dictionary (32nd ed.). Philadelphia, PA: Saunders/Elsevier; 2012.
88. Wiig H, Swartz MA. Interstitial fluid and lymph formation and transport: physiological regulation and roles in inflammation and cancer. Physiol Rev 2012;92(3):1005–1060.
89. Yao W, Li Y, Ding G. Interstitial Fluid Flow: The Mechanical Environment of Cells and Foundation of Meridians. Evidence-Based Complementary and Alternative Medicine. Volume 2012 (2012), Article ID 853516
90. Tarbell JM, Weinbaum S, Kamm RD. Cellular fluid mechanics and mechanotransduction. Ann Biomed Eng 2005;33(12):1719–1723.
91. Hillman RS, Ault KA, Rinder HM. Hematology in clinical practice: A guide to diagnosis and management (4th ed.). New York: McGraw-Hill Professional; 2005.
92. Pierigè F, Serafini S, Rossi L, Magnani M. Cell-based drug delivery. Adv Drug Deliv Rev 2008;60(2):286–385.
93. Marieb EN, Hoehn K. The cardiovascular system: blood vessels. Human anatomy & physiology, 10th ed. London: Pearson Education, Inc. 2016.
94. Marieb EN, Hoehn K. The cardiovascular system: blood vessels. Human anatomy & physiology, 9th ed. London: Pearson Education Inc. 2013 p. 712.
95. Lee C-Y, Herant M, Heinrich V. Target-specific mechanics of phagocytosis: protrusive neutrophil response to zymosan differs from the uptake of antibody-tagged pathogens. J Cell Sci 2011;124(Pt 7):1106–1108.
96. Herant M, Heinrich V, Dembo M. Mechanics of neutrophil phagocytosis: experiments and quantitative models. J Cell Sci 2006;119(Pt 9):1903–1913.
97. Minasyan H. Phagocytosis and oxycytosis: two arms of human innate immunity. Immunol Res 2018;66(2):271–280.
98. Huntington JA. Natural inhibitors of thrombin. Thromb Haemost 2014;111(4):583–589.
99. Beaulieu LM, Freedman JE. The role of inflammation in regulating platelet production and function: Toll-like receptors in platelets and megakaryocytes. Thromb Res 2010;125(3):205–209.
100. Hamzeh-Cognasse H, Damien P, Chabert A, Pozzetto B, Cognasse F, Garraud O. Platelets and infections—complex interactions with bacteria. Front Immunol 2015;6:82.
101. Arman M, Krauel K, Tilley DO, et al. Amplification of bacteria-induced platelet activation is triggered by FcγRIIA, integrin αIIbβ3, and platelet factor 4. Blood 2014;123(20):3166–3174.
102. Loof TG, Deicke C, Medina E. The role of coagulation/fibrinolysis during Streptococcus pyogenes infection. Front Cellular Infect Microbiol 2014;4:128.
103. Itoh S, Yokoyama R, Kamoshida G, et al. Staphylococcal superantigen-like protein 10 (SSL10) inhibits blood coagulation by binding to prothrombin and factor Xa via their γ-carboxyglutamic acid (Gla) domain. J Biol Chem 2013;288(30):21569–21580.
104. Mavrommatis AC, Theodoridis T, Orfanidou A, Roussos C, Christopoulou-Kokkinou V, Zakynthinos S. Coagulation system and platelets are fully activated in uncomplicated sepsis. Crit Care Med 2000;28(2):451–457.
105. Thomer L, Schneewind O, Missiakas D. Multiple ligands of von Willebrand factor-binding protein (vWbp) promote Staphylococcus aureus clot formation in human plasma. J Biol Chem 2013;288(39):28283–28292.
106. Berends ETM, Kuipers A, Ravesloot MM, Urbanus RT, Rooijakkers SHM. Bacteria under stress by complement and coagulation. FEMS Microbiol Rev 2014;38(6):1146–1171.
107. Wallis R, Mitchell DA, Schmid R, Schwaeble WJ, Keeble AH. Paths reunited: Initiation of the classical and lectin pathways of complement activation. Immunobiology 2010;215(1):1–11.
108. Remy KE, Qiu P, Li Y, Cui X, Eichacker PQ. B. anthracis associated cardiovascular dysfunction and shock: the potential contribution of both non-toxin and toxin components. BMC Med 2013;11:217–219.
109. Barnum SR. Complement: A primer for the coming therapeutic revolution. Pharmacol Ther 2017; Dec 1. pii: 172(16):63–66.
110. Ricklin D, Hajishengallis G, Yang K, Lambris JD. Complement: a key system for immune surveillance and homeostasis. Nat Immunol 2010;11(9):785–797.
111. Ghebrehiwet B. The complement system: an evolution in progress. F1000Res 2016;5:2840
112. Parente R, Clark SJ, Inforzato A, Day AJ. Complement factor H in host defense and immune evasion. Cell Mol Life Sci 2017;74(9):1605–1624.
113. Meri T, Amdahl H, Lehtinen MJ, et al. Microbes bind complement inhibitor factor H via a common site. PLoS Pathog 2013;9(4):e1003308
114. Amdahl H, Jongerius I, Meri T, et al. Staphylococcal Ecb protein and host complement regulator factor H enhance functions of each other in bacterial immune evasion. J Immunol 2013;191(4):1775–1784. Aug 15;
115. Agarwal V, Sroka M, Fulde M, Bergmann S, Riesbeck K, Blom A. Binding of Streptococcus pneumoniae endopeptidase O (PepO) to complement component C1q modulates the complement attack and promotes host cell adherence. J Biol Chem 2014;289(22):15833–15844.
116. Kang M, Ko Y-P, Liang X, et al. Collagen-binding microbial surface components recognizing adhesive matrix molecule (MSCRAMM) of Gram-positive bacteria inhibit complement activation via the classical pathway. J Biol Chem 2013;288(28):20520–20531.
117. Chung MC, Tonry JH, Narayanan A, et al. Bacillus anthracis interacts with plasmin(ogen) to evade C3b-dependent innate immunity. PLoS One 2011;6(3):e18119.
118. Jusko M, Potempa J, Kantyka T, et al. Staphylococcal proteases aid in evasion of the human complement system. J Innate Immun 2014;6(1):31–46.
119. Davies LC, Jenkins SJ, Allen JE, Taylor PR. Tissue-resident macrophages. Nat Immunol 2013;14(10):986–995.
120. Mills CD, Kincaid K, Alt JM, Heilman MJ, Hill AM. M-1/M-2 macrophages and the Th1/Th2 paradigm. J Immunol 2000;164(12):6166–6173.
121. Takeuchi O, Akira S. Pattern recognition receptors and inflammation. Cell 2010;140(6):805–820.
122. Aderem A, Underhill DM. Mechanisms of phagocytosis in macrophages. Annu Rev Immunol 1999;17:593–623.
123. Kim DC, Luster AD. The role of tissue resident cells in neutrophil recruitment. Trends Immunol 2015;36(9):547–555.
124. Cox D, Kerrigan SW, Watson SP. Platelets and the innate immune system: mechanisms of bacterial-induced platelet activation. J Thromb Haemost 2011;9(6):1097–1107.
125. Vicsek T, Zafeiris A. Collective Motion. Phys Rep 2012;517(3-4):71.
126. Dombrowski C, Cisneros L, Chatkaew S, Goldstein RE, Kessler JO. Self-concentration and large-scale coherence in bacterial dynamics. Phys Rev Lett 2004;93(9):098103
127. Borregaard N. Neutrophils, from marrow to microbes. Immunity 2010;33(5):657–670.
128. Yipp BG, Petri B, Salina D, et al. Infection-induced NETosis is a dynamic process involving NEUTROPHIL MULTITASKING IN VIVO. Nat Med 2012;18(9):1386–1393.
129. Brinkmann V, Reichard U, Goosmann C, et al. Neutrophil extracellular traps kill bacteria. Science 2004;303(5663):1532–1535. 03-05;AAAS.
130. Martinod K, Wagner DD. Thrombosis: tangled up in NETs. Blood 2014;123(18):2768–2776.
131. Bayer AS, Ramos MD, Menzies BE, Yeaman MR, Shen AJ, Cheung AL. Hyperproduction of alpha-toxin by Staphylococcus aureus results in paradoxically reduced virulence in experimental endocarditis: a host defense role for platelet microbicidal proteins. Infect Immun 1997;65(11):4652–4660.
132. Bryant AE, Bayer CR, Chen RY, Guth PH, Wallace RJ, Stevens DL. Vascular dysfunction and ischemic destruction of tissue in Streptococcus pyogenes infection: the role of streptolysin O-induced platelet/neutrophil complexes. J Infect Dis 2005;192(6):1014–1022.
133. Brauckmann S, Effenberger-Neidnicht K, de Groot H, et al. Lipopolysaccharide-induced hemolysis: Evidence for direct membrane interactions. Sci Rep 2016;6:35508.
134. Rother RP, Bell L, Hillmen P, Gladwin MT. The clinical sequelae of intravascular hemolysis and extracellular plasma hemoglobin: a novel mechanism of human disease. JAMA 2005;293(13):1653–1662.
135. Misztal T, Tomasiak M. Pathophysiological consequences of hemolysis. Role of cell-free hemoglobin. Postepy Hig Med Dosw 2011;65:627–639.
136. Lin T, Kwak YH, Sammy F, et al. Synergistic inflammation is induced by blood degradation products with microbial toll-like receptor agonists and is blocked by hemopexin. J Infect Dis 2010;202(4):624–632.
137. Dutra FF, Alves LS, Rodrigues D, et al. Hemolysis-induced lethality involves inflammasome activation by heme. Proc Natl Acad Sci USA 2014;111(39):E4110–E4118.
138. Hvidberg V, Maniecki MB, Jacobsen C, Højrup P, Møller HJ, Moestrup SK. Identification of the receptor scavenging hemopexin-heme complexes. Blood 2005;106(7):2572–2579.
139. Janz DR, Bastarache JA, Peterson JF, et al. Association between cell-free hemoglobin, acetaminophen, and mortality in patients with sepsis: an observational study. Crit Care Med 2013;41(3):784–790.
140. Adamzik M, Hamburger T, Petrat F, Peters J, de Groot H, Hartmann M. Free hemoglobin concentration in severe sepsis: methods of measurement and prediction of outcome. Crit Care 2012;16(4):R125
141. Larsen R, Gozzelino R, Jeney V, et al. Soares MP A central role for free heme in the pathogenesis of severe sepsis. Sci Transl Med 2010;2(51):51–71..
142. Lin T, Maita D, Thundivalappil SR, et al. Hemopexin in severe inflammation and infection: mouse models and human diseases. Crit Care 2015;19:166.
143. Vinchi F, De Franceschi L, Ghigo A, et al. Hemopexin therapy improves cardiovascular function by preventing heme-induced endothelial toxicity in mouse models of hemolytic diseases. Circulation 2013;127(12):1317–1329.
144. Speth C, Löffler J, Krappmann S, Lass-Flörl C, Rambach G. Platelets as Immune Cells in Infectious Diseases. Future Microbiol 2013;8(11):1431–1451.
145. Kraemer BF, Campbell RA, Schwertz H, et al. Bacteria differentially induce degradation of Bcl-xL, a survival protein, by human platelets. Blood 2012;120(25):5014–5020.,.
146. Esmon CT. Interactions between the innate immune and blood coagulation systems. Trends Immunol2004;25(10):536–542.
147. Engelmann B, Massberg S. Thrombosis as an intravascular effector of innate immunity. Nat Rev Immunol 2013;13(1):34–45.
148. Ito T. PAMPs and DAMPs as triggers for DIC. J Intensive Care 2014;2(1):65.
149. Semeraro N, Ammollo CT, Semeraro F, Colucci M. Sepsis, thrombosis and organ dysfunction. Thromb Res 2012;129(3):290–295.
150. Lupu F, Keshari RS, Lambris JD, Coggeshall KM. Crosstalk between the coagulation and complement systems in sepsis. Thromb Res 2014;133(1):28–31.
151. Muta T, Iwanaga S. The role of hemolymph coagulation in innate immunity. Curr Opin Immunol 1996;8(1):41–47.
152. Towhid ST, Nega M, Schmidt E-M, et al. Stimulation of platelet apoptosis by peptidoglycan from Staphylococcus aureus 113. Apoptosis 2012;17(9):998–1008.
153. Lee SP, Ataga KI, Orringer EP, Phillips DR, Parise LV. Biologically active CD40 ligand is elevated in sickle cell anemia: potential role for platelet-mediated inflammation. Arterioscler Thromb Vasc Biol 2006;26(7):1626–1631.
154. Esmon CT. Molecular circuits in thrombosis and inflammation. Thromb Haemost 2013;109(3):416–420.
155. Stief TW. Thrombin generation by hemolysis. Blood Coagul Fibrinolysis 2007;18(1):61–66.
156. McDonald K, Cullinane AM, Merryman PK, Hoddeson EK. The effect of red blood cells on thrombin generation. Br J Haematol 2006;133(4):403–408.
157. Pfeiler S, Massberg S, Engelmann B. Biological basis and pathological relevance of microvascular thrombosis. Thromb Res 2014;133(Suppl 1):S35–S37.
158. Nieuwland R, Berckmans RJ, McGregor S, et al. Cellular origin and procoagulant properties of microparticles in meningococcal sepsis. Blood 2000;95(3):930–935.:
159. Bryant A. Biology and pathogenesis of thrombosis and procoagulant activity in invasive infections caused by group A streptococci and Clostridium perfringens. Clin Microbiol Rev 2003;16(3):451–462.